{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:29:38Z","timestamp":1787970578776,"version":"build-2784847793"},"reference-count":148,"publisher":"Keio Journal of Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Keio J. Med.","Keio j. med"],"published-print":{"date-parts":[[2023]]},"DOI":"10.2302\/kjm.2022-0015-ir","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T22:14:38Z","timestamp":1678400078000},"page":"29-43","source":"Crossref","is-referenced-by-count":4,"title":["Network Approaches to Uncover Pathogenesis and Therapeutic Targets of          Inflammatory Bowel Diseases"],"prefix":"10.2302","volume":"72","author":[{"given":"Yohei","family":"Mikami","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department              of Internal Medicine, Keio University School of Medicine, Tokyo,            Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Kanai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department              of Internal Medicine, Keio University School of Medicine, Tokyo,            Japan"},{"name":"AMED-CREST, Japan Agency for Medical Research and              Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1082","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kamada N, Seo SU, Chen GY, N\u00fa\u00f1ez G: Role of the          gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 2013; 13: 321\u2013335.          PMID:23618829 https:\/\/doi.org\/10.1038\/nri3430","DOI":"10.1038\/nri3430"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. O\u2019Shea JJ, Paul WE: Mechanisms underlying lineage          commitment and plasticity of helper CD4+ T cells. Science 2010; 327: 1098\u20131102.          PMID:20185720 https:\/\/doi.org\/10.1126\/science.1178334","DOI":"10.1126\/science.1178334"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Neurath MF, Weigmann B, Finotto S, Glickman J,          Nieuwenhuis E, Iijima H, Mizoguchi A, Mizoguchi E, Mudter J, Galle PR, Bhan A, Autschbach          F, Sullivan BM, Szabo SJ, Glimcher LH, Blumberg RS: The transcription factor T-bet          regulates mucosal T cell activation in experimental colitis and Crohn\u2019s disease. J Exp Med          2002; 195: 1129\u20131143. PMID:11994418 https:\/\/doi.org\/10.1084\/jem.20011956","DOI":"10.1084\/jem.20011956"},{"key":"4","unstructured":"4. Kobayashi K, Asakura H, Hamada Y, Hibi T,          Watanabe M, Yoshida T, Watanabe N, Miura S, Aiso S, Tsuchiya M: T lymphocyte          subpopulations and immunoglobulin-containing cells in the colonic mucosa of ulcerative          colitis; a morphometric and immunohistochemical study. J Clin Lab Immunol 1988; 25: 63\u201368.          PMID:2897471"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Uo M, Hisamatsu T, Miyoshi J, Kaito D, Yoneno K,          Kitazume MT, Mori M, Sugita A, Koganei K, Matsuoka K, Kanai T, Hibi T: Mucosal CXCR4+ IgG          plasma cells contribute to the pathogenesis of human ulcerative colitis through          Fc\u03b3R-mediated CD14 macrophage activation. Gut 2013; 62: 1734\u20131744. PMID:23013725          https:\/\/doi.org\/10.1136\/gutjnl-2012-303063","DOI":"10.1136\/gutjnl-2012-303063"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kett K, Rognum TO, Brandtzaeg P: Mucosal subclass          distribution of immunoglobulin G-producing cells is different in ulcerative colitis and          Crohn\u2019s disease of the colon. Gastroenterology 1987; 93: 919\u2013924. PMID:3308623          https:\/\/doi.org\/10.1016\/0016-5085(87)90552-X","DOI":"10.1016\/0016-5085(87)90552-X"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Mosmann TR, Coffman RL: TH1 and TH2 cells:          different patterns of lymphokine secretion lead to different functional properties. Annu          Rev Immunol 1989; 7: 145\u2013173. PMID:2523712          https:\/\/doi.org\/10.1146\/annurev.iy.07.040189.001045","DOI":"10.1146\/annurev.iy.07.040189.001045"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fuss IJ: Is the Th1\/Th2 paradigm of immune          regulation applicable to IBD? Inflamm Bowel Dis 2008; 14: S110\u2013S112. PMID:18816734          https:\/\/doi.org\/10.1097\/00054725-200810001-00054","DOI":"10.1002\/ibd.20683"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lees CW, Barrett JC, Parkes M, Satsangi J: New          IBD genetics: common pathways with other diseases. Gut 2011; 60: 1739\u20131753. PMID:21300624          https:\/\/doi.org\/10.1136\/gut.2009.199679","DOI":"10.1136\/gut.2009.199679"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kobayashi T, Okamoto S, Hisamatsu T, Kamada N,          Chinen H, Saito R, Kitazume MT, Nakazawa A, Sugita A, Koganei K, Isobe K, Hibi T: IL23          differentially regulates the Th1\/Th17 balance in ulcerative colitis and Crohn\u2019s disease.          Gut 2008; 57: 1682\u20131689. PMID:18653729          https:\/\/doi.org\/10.1136\/gut.2007.135053","DOI":"10.1136\/gut.2007.135053"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K,          Araki Y, Bamba T, Fujiyama Y: Increased expression of interleukin 17 in inflammatory bowel          disease. Gut 2003; 52: 65\u201370. PMID:12477762          https:\/\/doi.org\/10.1136\/gut.52.1.65","DOI":"10.1136\/gut.52.1.65"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Rovedatti L, Kudo T, Biancheri P, Sarra M,          Knowles CH, Rampton DS, Corazza GR, Monteleone G, Di Sabatino A, MacDonald TT:          Differential regulation of interleukin 17 and interferon gamma production in inflammatory          bowel disease. Gut 2009; 58: 1629\u20131636. PMID:19740775          https:\/\/doi.org\/10.1136\/gut.2009.182170","DOI":"10.1136\/gut.2009.182170"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima          T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda          K, Umesaki Y, Honda K, Littman DR: Induction of intestinal Th17 cells by segmented          filamentous bacteria. Cell 2009; 139: 485\u2013498. PMID:19836068          https:\/\/doi.org\/10.1016\/j.cell.2009.09.033","DOI":"10.1016\/j.cell.2009.09.033"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Atarashi K, Tanoue T, Ando M, Kamada N, Nagano Y,          Narushima S, Suda W, Imaoka A, Setoyama H, Nagamori T, Ishikawa E, Shima T, Hara T, Kado          S, Jinnohara T, Ohno H, Kondo T, Toyooka K, Watanabe E, Yokoyama S, Tokoro S, Mori H,          Noguchi Y, Morita H, Ivanov II, Sugiyama T, Nu\u00f1ez G, Camp JG, Hattori M, Umesaki Y, Honda          K: Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell 2015;          163: 367\u2013380. PMID:26411289 https:\/\/doi.org\/10.1016\/j.cell.2015.08.058","DOI":"10.1016\/j.cell.2015.08.058"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE,          Lepelley A, Lafaille JJ, Cua DJ, Littman DR: The orphan nuclear receptor RORgammat directs          the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126:          1121\u20131133. PMID:16990136 https:\/\/doi.org\/10.1016\/j.cell.2006.07.035","DOI":"10.1016\/j.cell.2006.07.035"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Stockinger B, Omenetti S: The dichotomous nature          of T helper 17 cells. Nat Rev Immunol 2017; 17: 535\u2013544. PMID:28555673          https:\/\/doi.org\/10.1038\/nri.2017.50","DOI":"10.1038\/nri.2017.50"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Powrie F, Leach MW, Mauze S, Caddie LB, Coffman          RL: Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic          intestinal inflammation in C. B-17 scid mice. Int Immunol 1993; 5: 1461\u20131471. PMID:7903159          https:\/\/doi.org\/10.1093\/intimm\/5.11.1461","DOI":"10.1093\/intimm\/5.11.1461"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Leppkes M, Becker C, Ivanov II, Hirth S, Wirtz S,          Neufert C, Pouly S, Murphy AJ, Valenzuela DM, Yancopoulos GD, Becher B, Littman DR,          Neurath MF: ROR\u03b3-expressing Th17 cells induce murine chronic intestinal inflammation via          redundant effects of IL-17A and IL-17F. Gastroenterology 2009; 136: 257\u2013267. PMID:18992745          https:\/\/doi.org\/10.1053\/j.gastro.2008.10.018","DOI":"10.1053\/j.gastro.2008.10.018"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. O\u2019Connor W, Jr, Kamanaka M, Booth CJ, Town T,          Nakae S, Iwakura Y, Kolls JK, Flavell RA: A protective function for interleukin 17A in T          cell-mediated intestinal inflammation. Nat Immunol 2009; 10: 603\u2013609. PMID:19448631          https:\/\/doi.org\/10.1038\/ni.1736","DOI":"10.1038\/ni.1736"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y:          Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in          mice. Clin Immunol 2004; 110: 55\u201362. PMID:14962796          https:\/\/doi.org\/10.1016\/j.clim.2003.09.013","DOI":"10.1016\/j.clim.2003.09.013"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke          M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J,          Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis          SP, Secukinumab in Crohn\u2019s Disease Study Group: Secukinumab, a human anti-IL-17A          monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a          randomised, double-blind placebo-controlled trial. Gut 2012; 61: 1693\u20131700. PMID:22595313          https:\/\/doi.org\/10.1136\/gutjnl-2011-301668","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB,          Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of          pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235\u2013238. PMID:16648838          https:\/\/doi.org\/10.1038\/nature04753","DOI":"10.1038\/nature04753"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ghoreschi K, Laurence A, Yang XP, Tato CM,          McGeachy MJ, Konkel JE, Ramos HL, Wei L, Davidson TS, Bouladoux N, Grainger JR, Chen Q,          Kanno Y, Watford WT, Sun HW, Eberl G, Shevach EM, Belkaid Y, Cua DJ, Chen W, O\u2019Shea JJ:          Generation of pathogenic TH17 cells in the absence of TGF-\u03b2 signalling. Nature 2010; 467:          967\u2013971. PMID:20962846 https:\/\/doi.org\/10.1038\/nature09447","DOI":"10.1038\/nature09447"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Esplugues E, Huber S, Gagliani N, Hauser AE, Town          T, Wan YY, O\u2019Connor W, Rongvaux A, Van Rooijen N, Haberman AM, Iwakura Y, Kuchroo VK,          Kolls JK, Bluestone JA, Herold KC, Flavell RA: Control of TH17 cells occurs in the small          intestine. Nature 2011; 475: 514\u2013518. PMID:21765430          https:\/\/doi.org\/10.1038\/nature10228","DOI":"10.1038\/nature10228"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Gaublomme JT, Yosef N, Lee Y, Gertner RS, Yang          LV, Wu C, Pandolfi PP, Mak T, Satija R, Shalek AK, Kuchroo VK, Park H, Regev A:          Single-cell genomics unveils critical regulators of Th17 cell pathogenicity. Cell 2015;          163: 1400\u20131412. PMID:26607794 https:\/\/doi.org\/10.1016\/j.cell.2015.11.009","DOI":"10.1016\/j.cell.2015.11.009"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lee YK, Turner H, Maynard CL, Oliver JR, Chen D,          Elson CO, Weaver CT: Late developmental plasticity in the T helper 17 lineage. Immunity          2009; 30: 92\u2013107. PMID:19119024          https:\/\/doi.org\/10.1016\/j.immuni.2008.11.005","DOI":"10.1016\/j.immuni.2008.11.005"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Mikami Y, Philips RL, Scium\u00e8 G, Petermann F,          Meylan F, Nagashima H, Yao C, Davis FP, Brooks SR, Sun HW, Takahashi H, Poholek AC, Shih          HY, Afzali B, Muljo SA, Hafner M, Kanno Y, O\u2019Shea JJ: MicroRNA-221 and -222 modulate          intestinal inflammatory Th17 cell response as negative feedback regulators downstream of          interleukin-23. Immunity 2021; 54: 514\u2013525. PMID:33657395          https:\/\/doi.org\/10.1016\/j.immuni.2021.02.015","DOI":"10.1016\/j.immuni.2021.02.015"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Kiner E, Willie E, Vijaykumar B, Chowdhary K,          Schmutz H, Chandler J, Schnell A, Thakore PI, LeGros G, Mostafavi S, Mathis D, Benoist C,          Immunological Genome Project Consortium: Gut CD4+ T cell phenotypes are a continuum molded          by microbes, not by TH archetypes. Nat Immunol 2021; 22: 216\u2013228. PMID:33462454          https:\/\/doi.org\/10.1038\/s41590-020-00836-7","DOI":"10.1038\/s41590-021-00916-2"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Langrish CL, Chen Y, Blumenschein WM, Mattson J,          Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ: IL-23 drives a pathogenic T          cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233\u2013240.          PMID:15657292 https:\/\/doi.org\/10.1084\/jem.20041257","DOI":"10.1084\/jem.20041257"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y,          Cua DJ, Ahlfors H, Wilhelm C, Tolaini M, Menzel U, Garefalaki A, Potocnik AJ, Stockinger          B: Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 2011;          12: 255\u2013263. PMID:21278737 https:\/\/doi.org\/10.1038\/ni.1993","DOI":"10.1038\/ni.1993"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai          F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M,          Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi K,          Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T: Evidence-based clinical          practice guidelines for inflammatory bowel disease. J Gastroenterol 2018; 53: 305\u2013353.          PMID:29429045 https:\/\/doi.org\/10.1007\/s00535-018-1439-1","DOI":"10.1007\/s00535-018-1439-1"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Ko CW, Singh S, Feuerstein JD, Falck-Ytter C,          Falck-Ytter Y, Cross RK: AGA clinical practice guidelines on the management of          mild-to-moderate ulcerative colitis. Gastroenterology 2019; 156: 748\u2013764. PMID:30576644          https:\/\/doi.org\/10.1053\/j.gastro.2018.12.009","DOI":"10.1053\/j.gastro.2018.12.009"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Harbord M, Eliakim R, Bettenworth D, Karmiris K,          Katsanos K, Kopylov U, Kucharzik T, Moln\u00e1r T, Raine T, Sebastian S, de Sousa HT, Dignass          A, Carbonnel F, European Crohn\u2019s and Colitis Organisation [ECCO]: Third European          evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2:          current management. J Crohn\u2019s Colitis 2017; 11: 769\u2013784. PMID:28513805          https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx009","DOI":"10.1093\/ecco-jcc\/jjx009"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Nakase H, Uchino M, Shinzaki S, Matsuura M,          Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji          T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H,          Enomoto N, Shimosegawa T, Koike K: Evidence-based clinical practice guidelines for          inflammatory bowel disease 2020. J Gastroenterol 2021; 56: 489\u2013526. PMID:33885977          https:\/\/doi.org\/10.1007\/s00535-021-01784-1","DOI":"10.1007\/s00535-021-01784-1"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Paramsothy S, Rosenstein AK, Mehandru S, Colombel          JF: The current state of the art for biological therapies and new small molecules in          inflammatory bowel disease. Mucosal Immunol 2018; 11: 1558\u20131570. PMID:29907872          https:\/\/doi.org\/10.1038\/s41385-018-0050-3","DOI":"10.1038\/s41385-018-0050-3"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf          DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR: Etanercept for active          Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology          2001; 121: 1088\u20131094. PMID:11677200          https:\/\/doi.org\/10.1053\/gast.2001.28674","DOI":"10.1053\/gast.2001.28674"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Van den Brande JM, Braat H, van den Brink GR,          Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van          Deventer SJ: Infliximab but not etanercept induces apoptosis in lamina propria          T-lymphocytes from patients with Crohn\u2019s disease. Gastroenterology 2003; 124: 1774\u20131785.          PMID:12806611 https:\/\/doi.org\/10.1016\/S0016-5085(03)00382-2","DOI":"10.1016\/S0016-5085(03)00382-2"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. van Straalen JW, Krol RM, Giancane G, Panaviene          V, Ailioaie LM, Dole\u017ealov\u00e1 P, Cattalini M, Susic G, Sztajnbok FR, Maritsi D, Constantin T,          Sawhney S, Rygg M, Oliveira SK, Nordal EB, Saad-Magalh\u00e3es C, Rubio-Perez N, Jelusic M, de          Roock S, Wulffraat NM, Ruperto N, Swart JF: Increased incidence of inflammatory bowel          disease on etanercept in juvenile idiopathic arthritis regardless of concomitant          methotrexate use. Rheumatology (Oxford) 2022; 61: 2104\u20132112. PMID:34508559          https:\/\/doi.org\/10.1093\/rheumatology\/keab678","DOI":"10.1093\/rheumatology\/keab678"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Digby-Bell JL, Atreya R, Monteleone G, Powell N:          Interrogating host immunity to predict treatment response in inflammatory bowel disease.          Nat Rev Gastroenterol Hepatol 2020; 17: 9\u201320. PMID:31767987          https:\/\/doi.org\/10.1038\/s41575-019-0228-5","DOI":"10.1038\/s41575-019-0228-5"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Schett G, McInnes IB, Neurath MF: Reframing          immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med 2021;          385: 628\u2013639. PMID:34379924 https:\/\/doi.org\/10.1056\/NEJMra1909094","DOI":"10.1056\/NEJMra1909094"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K,          Lennerz JK, Doherty JM, Mills JC, Colonna M: A human natural killer cell subset provides          an innate source of IL-22 for mucosal immunity. Nature 2009; 457: 722\u2013725. PMID:18978771          https:\/\/doi.org\/10.1038\/nature07537","DOI":"10.1038\/nature07537"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Mizuno S, Mikami Y, Kamada N, Handa T, Hayashi A,          Sato T, Matsuoka K, Matano M, Ohta Y, Sugita A, Koganei K, Sahara R, Takazoe M, Hisamatsu          T, Kanai T: Cross-talk between ROR\u03b3t+ innate lymphoid cells and intestinal macrophages          induces mucosal IL-22 production in Crohn\u2019s disease. Inflamm Bowel Dis 2014; 20:          1426\u20131434. PMID:24991784 https:\/\/doi.org\/10.1097\/MIB.0000000000000105","DOI":"10.1097\/MIB.0000000000000105"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Basu R, O\u2019Quinn DB, Silberger DJ, Schoeb TR,          Fouser L, Ouyang W, Hatton RD, Weaver CT: Th22 cells are an important source of IL-22 for          host protection against enteropathogenic bacteria. Immunity 2012; 37: 1061\u20131075.          PMID:23200827 https:\/\/doi.org\/10.1016\/j.immuni.2012.08.024","DOI":"10.1016\/j.immuni.2012.08.024"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Zenewicz LA, Yancopoulos GD, Valenzuela DM,          Murphy AJ, Stevens S, Flavell RA: Innate and adaptive interleukin-22 protects mice from          inflammatory bowel disease. Immunity 2008; 29: 947\u2013957. PMID:19100701          https:\/\/doi.org\/10.1016\/j.immuni.2008.11.003","DOI":"10.1016\/j.immuni.2008.11.003"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Sawa S, Lochner M, Satoh-Takayama N, Dulauroy S,          B\u00e9rard M, Kleinschek M, Cua D, Di Santo JP, Eberl G: ROR\u03b3t+ innate lymphoid cells regulate          intestinal homeostasis by integrating negative signals from the symbiotic microbiota. Nat          Immunol 2011; 12: 320\u2013326. PMID:21336274 https:\/\/doi.org\/10.1038\/ni.2002","DOI":"10.1038\/ni.2002"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y,          Andoh A, Bhan AK, Blumberg RS, Xavier RJ, Mizoguchi A: IL-22 ameliorates intestinal          inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008; 118: 534\u2013544.          PMID:18172556 https:\/\/doi.org\/10.1172\/JCI33194","DOI":"10.1172\/JCI33194"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Lindemans CA, Calafiore M, Mertelsmann AM,          O\u2019Connor MH, Dudakov JA, Jenq RR, Velardi E, Young LF, Smith OM, Lawrence G, Ivanov JA, Fu          YY, Takashima S, Hua G, Martin ML, O\u2019Rourke KP, Lo YH, Mokry M, Romera-Hernandez M, Cupedo          T, Dow LE, Nieuwenhuis EE, Shroyer NF, Liu C, Kolesnick R, van den Brink MR, Hanash AM:          Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. Nature          2015; 528: 560\u2013564. PMID:26649819 https:\/\/doi.org\/10.1038\/nature16460","DOI":"10.1038\/nature16460"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. He GW, Lin L, DeMartino J, Zheng X, Staliarova N,          Dayton T, Begthel H, van de Wetering WJ, Bodewes E, van Zon J, Tans S, Lopez-Iglesias C,          Peters PJ, Wu W, Kotlarz D, Klein C, Margaritis T, Holstege F, Clevers H: Optimized human          intestinal organoid model reveals interleukin-22-dependency of Paneth cell formation. Cell          Stem Cell 2022; 29: 1333\u20131345. PMID:36002022          https:\/\/doi.org\/10.1016\/j.stem.2022.08.002","DOI":"10.1016\/j.stem.2022.08.002"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Gaudino SJ, Beaupre M, Lin X, Joshi P, Rathi S,          McLaughlin PA, Kempen C, Mehta N, Eskiocak O, Yueh B, Blumberg RS, van der Velden AW,          Shroyer KR, Bialkowska AB, Beyaz S, Kumar P: IL-22 receptor signaling in Paneth cells is          critical for their maturation, microbiota colonization, Th17-related immune responses, and          anti-Salmonella immunity. Mucosal Immunol 2021; 14: 389\u2013401. PMID:33060802          https:\/\/doi.org\/10.1038\/s41385-020-00348-5","DOI":"10.1038\/s41385-020-00348-5"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Cox JH, Kljavin NM, Ota N, Leonard J, Roose-Girma          M, Diehl L, Ouyang W, Ghilardi N: Opposing consequences of IL-23 signaling mediated by          innate and adaptive cells in chemically induced colitis in mice. Mucosal Immunol 2012; 5:          99\u2013109. PMID:22089030 https:\/\/doi.org\/10.1038\/mi.2011.54","DOI":"10.1038\/mi.2011.54"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Eken A, Singh AK, Treuting PM, Oukka M: IL-23R+          innate lymphoid cells induce colitis via interleukin-22-dependent mechanism. Mucosal          Immunol 2014; 7: 143\u2013154. PMID:23715173          https:\/\/doi.org\/10.1038\/mi.2013.33","DOI":"10.1038\/mi.2013.33"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Reyes JL, Fernando MR, Lopes F, Leung G, Mancini          NL, Matisz CE, Wang A, McKay DM: IL-22 restrains tapeworm-mediated protection against          experimental colitis via regulation of IL-25 expression. PLoS Pathog 2016; 12: e1005481.          PMID:27055194 https:\/\/doi.org\/10.1371\/journal.ppat.1005481","DOI":"10.1371\/journal.ppat.1005481"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Pavlidis P, Tsakmaki A, Pantazi E, Li K, Cozzetto          D, Digby-Bell J, Yang F, Lo JW, Alberts E, Sa AC, Niazi U, Friedman J, Long AK, Ding Y,          Carey CD, Lamb C, Saqi M, Madgwick M, Gul L, Treveil A, Korcsmaros T, Macdonald TT, Lord          GM, Bewick G, Powell N: Interleukin-22 regulates neutrophil recruitment in ulcerative          colitis and is associated with resistance to ustekinumab therapy. Nat Commun 2022; 13:          5820. PMID:36192482 https:\/\/doi.org\/10.1038\/s41467-022-33331-8","DOI":"10.1038\/s41467-022-33331-8"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Feagan BG, Rutgeerts P, Sands BE, Hanauer S,          Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh          S, Wyant T, Xu J, Parikh A, GEMINI 1 Study Group: Vedolizumab as induction and maintenance          therapy for ulcerative colitis. N Engl J Med 2013; 369: 699\u2013710. PMID:23964932          https:\/\/doi.org\/10.1056\/NEJMoa1215734","DOI":"10.1056\/NEJMoa1215734"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S,          Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S,          Xu J, Stephens K, Milch C, Parikh A, GEMINI 2 Study Group: Vedolizumab as induction and          maintenance therapy for Crohn\u2019s disease. N Engl J Med 2013; 369: 711\u2013721. PMID:23964933          https:\/\/doi.org\/10.1056\/NEJMoa1215739","DOI":"10.1056\/NEJMoa1215739"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Matsuoka K, Watanabe M, Ohmori T, Nakajima K,          Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S,          Miura Y, Ohta A, Kajioka T, Hibi T, AJM300 Study Group: AJM300 (carotegrast methyl), an          oral antagonist of \u03b14-integrin, as induction therapy for patients with moderately active          ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3          study. Lancet Gastroenterol Hepatol 2022; 7: 648\u2013657. PMID:35366419          https:\/\/doi.org\/10.1016\/S2468-1253(22)00022-X","DOI":"10.2139\/ssrn.3978554"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. R\u00f6nnblom L, Elkon KB: Cytokines as therapeutic          targets in SLE. Nat Rev Rheumatol 2010; 6: 339\u2013347. PMID:20440285          https:\/\/doi.org\/10.1038\/nrrheum.2010.64","DOI":"10.1038\/nrrheum.2010.64"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF,          Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I          Study Group: Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial.          Lancet 2002; 359: 1541\u20131549. PMID:12047962          https:\/\/doi.org\/10.1016\/S0140-6736(02)08512-4","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W,          Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers          WJ, Present D, Sands BE, Colombel JF: Infliximab for induction and maintenance therapy for          ulcerative colitis. N Engl J Med 2005; 353: 2462\u20132476. PMID:16339095          https:\/\/doi.org\/10.1056\/NEJMoa050516","DOI":"10.1056\/NEJMoa050516"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris          GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D\u2019Haens G, Diamond RH, Broussard DL, Tang          KL, van der Woude CJ, Rutgeerts P, SONIC Study Group: Infliximab, azathioprine, or          combination therapy for Crohn\u2019s disease. N Engl J Med 2010; 362: 1383\u20131395. PMID:20393175          https:\/\/doi.org\/10.1056\/NEJMoa0904492","DOI":"10.1056\/NEJMoa0904492"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Philips RL, Wang Y, Cheon H, Kanno Y, Gadina M,          Sartorelli V, Horvath CM, Darnell JE, Stark GR, O\u2019Shea JJ: The JAK\u2013STAT pathway at 30:          much learned, much more to do. Cell 2022; 185: 3857\u20133876. PMID:36240739          https:\/\/doi.org\/10.1016\/j.cell.2022.09.023","DOI":"10.1016\/j.cell.2022.09.023"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. O\u2019Shea JJ, Holland SM, Staudt LM: JAKs and STATs          in immunity, immunodeficiency, and cancer. N Engl J Med 2013; 368: 161\u2013170. PMID:23301733          https:\/\/doi.org\/10.1056\/NEJMra1202117","DOI":"10.1056\/NEJMra1202117"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. O\u2019Shea JJ, Schwartz DM, Villarino AV, Gadina M,          McInnes IB, Laurence A: The JAK\u2013STAT pathway: impact on human disease and therapeutic          intervention. Annu Rev Med 2015; 66: 311\u2013328. PMID:25587654          https:\/\/doi.org\/10.1146\/annurev-med-051113-024537","DOI":"10.1146\/annurev-med-051113-024537"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Villarino AV, Kanno Y, O\u2019Shea JJ: Mechanisms and          consequences of Jak\u2013STAT signaling in the immune system. Nat Immunol 2017; 18: 374\u2013384.          PMID:28323260 https:\/\/doi.org\/10.1038\/ni.3691","DOI":"10.1038\/ni.3691"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65.Villarino AV, Gadina M, O\u2019Shea JJ, Kanno Y.          SnapShot: Jak-STAT signaling II. Cell 2020; 181 : 1696\u20131696.e1.","DOI":"10.1016\/j.cell.2020.04.052"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Endo TA, Masuhara M, Yokouchi M, Suzuki R,          Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N,          Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A: A new protein containing an SH2          domain that inhibits JAK kinases. Nature 1997; 387: 921\u2013924. PMID:9202126          https:\/\/doi.org\/10.1038\/43213","DOI":"10.1038\/43213"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Yoshimura A, Ito M, Mise-Omata S, Ando M: SOCS:          negative regulators of cytokine signaling for immune tolerance. Int Immunol 2021; 33:          711\u2013716. PMID:34415326 https:\/\/doi.org\/10.1093\/intimm\/dxab055","DOI":"10.1093\/intimm\/dxab055"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK,          Arthur CD, King KL, Sheehan KC, Yin L, Pennica D, Johnson EM, Schreiber RD: Disruption of          the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in          cytokine-induced biologic responses. Cell 1998; 93: 373\u2013383. PMID:9590172          https:\/\/doi.org\/10.1016\/S0092-8674(00)81166-6","DOI":"10.1016\/S0092-8674(00)81166-6"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Neubauer H, Cumano A, M\u00fcller M, Wu H, Huffstadt          U, Pfeffer K: Jak2 deficiency defines an essential developmental checkpoint in definitive          hematopoiesis. Cell 1998; 93: 397\u2013409. PMID:9590174          https:\/\/doi.org\/10.1016\/S0092-8674(00)81168-X","DOI":"10.1016\/S0092-8674(00)81168-X"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Woellner C, Sch\u00e4ffer AA, Puck JM, Renner ED,          Knebel C, Holland SM, Plebani A, Grimbacher B: The hyper IgE syndrome and mutations in          TYK2. Immunity 2007; 26: 535. PMID:17521577          https:\/\/doi.org\/10.1016\/j.immuni.2007.05.007","DOI":"10.1016\/j.immuni.2007.05.007"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Pesu M, Candotti F, Husa M, Hofmann SR,          Notarangelo LD, O\u2019Shea JJ: Jak3, severe combined immunodeficiency, and a new class of          immunosuppressive drugs. Immunol Rev 2005; 203: 127\u2013142. PMID:15661026          https:\/\/doi.org\/10.1111\/j.0105-2896.2005.00220.x","DOI":"10.1111\/j.0105-2896.2005.00220.x"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Kawamura M, McVicar DW, Johnston JA, Blake TB,          Chen YQ, Lal BK, Lloyd AR, Kelvin DJ, Staples JE, Ortaldo JR: Molecular cloning of L-JAK,          a Janus family protein-tyrosine kinase expressed in natural killer cells and activated          leukocytes. Proc Natl Acad Sci USA 1994; 91: 6374\u20136378. PMID:8022790          https:\/\/doi.org\/10.1073\/pnas.91.14.6374","DOI":"10.1073\/pnas.91.14.6374"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Macchi P, Villa A, Giliani S, Sacco MG, Frattini          A, Porta F, Ugazio AG, Johnston JA, Candotti F, O\u2019Sheai JJ, Vezzoni P, Notarangelo LD:          Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency          (SCID). Nature 1995; 377: 65\u201368. PMID:7659163          https:\/\/doi.org\/10.1038\/377065a0","DOI":"10.1038\/377065a0"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Casanova JL, Holland SM, Notarangelo LD: Inborn          errors of human JAKs and STATs. Immunity 2012; 36: 515\u2013528. PMID:22520845          https:\/\/doi.org\/10.1016\/j.immuni.2012.03.016","DOI":"10.1016\/j.immuni.2012.03.016"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Hirahara K, Schwartz D, Gadina M, Kanno Y, O\u2019Shea          JJ: Targeting cytokine signaling in autoimmunity: back to the future and beyond. Curr Opin          Immunol 2016; 43: 89\u201397. PMID:27821272          https:\/\/doi.org\/10.1016\/j.coi.2016.10.001","DOI":"10.1016\/j.coi.2016.10.001"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Johnston JA, Kawamura M, Kirken RA, Chen YQ,          Blake TB, Shibuya K, Ortaldo JR, McVicar DW, O\u2019Shea JJ: Phosphorylation and activation of          the Jak-3 Janus kinase in response to interleukin-2. Nature 1994; 370: 151\u2013153.          PMID:8022485 https:\/\/doi.org\/10.1038\/370151a0","DOI":"10.1038\/370151a0"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Cohen AC, Nadeau KC, Tu W, Hwa V, Dionis K,          Bezrodnik L, Teper A, Gaillard M, Heinrich J, Krensky AM, Rosenfeld RG, Lewis DB: Cutting          edge: decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human          STAT5b deficiency. J Immunol 2006; 177: 2770\u20132774. PMID:16920911          https:\/\/doi.org\/10.4049\/jimmunol.177.5.2770","DOI":"10.4049\/jimmunol.177.5.2770"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Antov A, Yang L, Vig M, Baltimore D, Van Parijs          L: Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the          maintenance of self-tolerance. J Immunol 2003; 171: 3435\u20133441. PMID:14500638          https:\/\/doi.org\/10.4049\/jimmunol.171.7.3435","DOI":"10.4049\/jimmunol.171.7.3435"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Villarino A, Laurence A, Robinson GW, Bonelli M,          Dema B, Afzali B, Shih HY, Sun HW, Brooks SR, Hennighausen L, Kanno Y, O\u2019Shea JJ: Signal          transducer and activator of transcription 5 (STAT5) paralog dose governs T cell effector          and regulatory functions. eLife 2016; 5: e08384. PMID:26999798          https:\/\/doi.org\/10.7554\/eLife.08384","DOI":"10.7554\/eLife.08384"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Villarino AV, Scium\u00e8 G, Davis FP, Iwata S, Zitti          B, Robinson GW, Hennighausen L, Kanno Y, O\u2019Shea JJ: Subset- and tissue-defined STAT5          thresholds control homeostasis and function of innate lymphoid cells. J Exp Med 2017; 214:          2999\u20133014. PMID:28916644 https:\/\/doi.org\/10.1084\/jem.20150907","DOI":"10.1084\/jem.20150907"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Jostins L, Ripke S, Weersma RK, Duerr RH,          McGovern DP, Hui KY, Lee JC, Philip Schumm L, Sharma Y, Anderson CA, Essers J, Mitrovic M,          Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C,          Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L,          Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, B\u00fcning C, Cohain A, Cichon S,          D\u2019Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR,          Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A,          Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D,          Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri          O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD,          Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD,          Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ,          Zeissig S, Zhang B, Zhang CK, Zhao H, Silverberg MS, Annese V, Hakonarson H, Brant SR,          Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S,          Barrett JC, Cho JH, International IBD Genetics Consortium (IIBDGC): Host\u2013microbe          interactions have shaped the genetic architecture of inflammatory bowel disease. Nature          2012; 491: 119\u2013124. PMID:23128233 https:\/\/doi.org\/10.1038\/nature11582","DOI":"10.1038\/nature11582"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Graham DB, Xavier RJ: Pathway paradigms revealed          from the genetics of inflammatory bowel disease. Nature 2020; 578: 527\u2013539. PMID:32103191          https:\/\/doi.org\/10.1038\/s41586-020-2025-2","DOI":"10.1038\/s41586-020-2025-2"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Winthrop KL: The emerging safety profile of JAK          inhibitors in rheumatic disease. Nat Rev Rheumatol 2017; 13: 234\u2013243. PMID:28250461          https:\/\/doi.org\/10.1038\/nrrheum.2017.23","DOI":"10.1038\/nrrheum.2017.23"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina          M, O\u2019Shea JJ: Erratum: JAK inhibition as a therapeutic strategy for immune and          inflammatory diseases. Nat Rev Drug Discov 2018; 17: 78. PMID:29282366          https:\/\/doi.org\/10.1038\/nrd.2017.267","DOI":"10.1038\/nrd.2017.267"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Schwartz DM, Bonelli M, Gadina M, O\u2019Shea JJ: Type          I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev          Rheumatol 2016; 12: 25\u201336. PMID:26633291          https:\/\/doi.org\/10.1038\/nrrheum.2015.167","DOI":"10.1038\/nrrheum.2015.167"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Karaman MW, Herrgard S, Treiber DK, Gallant P,          Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt          JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM,          Zarrinkar PP: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol          2008; 26: 127\u2013132. PMID:18183025 https:\/\/doi.org\/10.1038\/nbt1358","DOI":"10.1038\/nbt1358"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Mikami Y, Scarno G, Zitti B, Shih HY, Kanno Y,          Santoni A, O\u2019Shea JJ, Scium\u00e8 G: NCR+ ILC3 maintain larger STAT4 reservoir via T\u2010BET to          regulate type 1 features upon IL\u201023 stimulation in mice. Eur J Immunol 2018; 48:          1174\u20131180. PMID:29524223 https:\/\/doi.org\/10.1002\/eji.201847480","DOI":"10.1002\/eji.201847480"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Lim AI, Li Y, Lopez-Lastra S, Stadhouders R, Paul          F, Casrouge A, Serafini N, Puel A, Bustamante J, Surace L, Masse-Ranson G, David E,          Strick-Marchand H, Le Bourhis L, Cocchi R, Topazio D, Graziano P, Muscarella LA, Rogge L,          Norel X, Sallenave JM, Allez M, Graf T, Hendriks RW, Casanova JL, Amit I, Yssel H, Di          Santo JP: Systemic human ILC precursors provide a substrate for tissue ILC          differentiation. Cell 2017; 168: 1086\u20131100. PMID:28283063          https:\/\/doi.org\/10.1016\/j.cell.2017.02.021","DOI":"10.1016\/j.cell.2017.02.021"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89.Gury-BenAri M, Thaiss CA, Serafini N, Winter          DR, Giladi A, Lara-Astiaso D, Levy M, Salame TM, Weiner A, David E,et al. The spectrum and          regulatory landscape of intestinal innate lymphoid cells are shaped by the microbiome.          Cell 2016; 166 : 1231\u20131246.","DOI":"10.1016\/j.cell.2016.07.043"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Scium\u00e8 G, Mikami Y, Jankovic D, Nagashima H,          Villarino AV, Morrison T, Yao C, Signorella S, Sun HW, Brooks SR, Fang D, Sartorelli V,          Nakayamada S, Hirahara K, Zitti B, Davis FP, Kanno Y, O\u2019Shea JJ, Shih HY: Rapid enhancer          remodeling and transcription factor repurposing enable high magnitude gene induction upon          acute activation of NK cells. Immunity 2020; 53: 745\u2013758. PMID:33010223          https:\/\/doi.org\/10.1016\/j.immuni.2020.09.008","DOI":"10.1016\/j.immuni.2020.09.008"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Shih HY, Scium\u00e8 G, Mikami Y, Guo L, Sun HW,          Brooks SR, Urban JF, Davis FP, Kanno Y, O\u2019Shea JJ: Developmental acquisition of regulomes          underlies innate lymphoid cell functionality. Cell 2016; 165: 1120\u20131133. PMID:27156451          https:\/\/doi.org\/10.1016\/j.cell.2016.04.029","DOI":"10.1016\/j.cell.2016.04.029"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Hnisz D, Day DS, Young RA: Insulated          neighborhoods: structural and functional units of mammalian gene control. Cell 2016; 167:          1188\u20131200. PMID:27863240 https:\/\/doi.org\/10.1016\/j.cell.2016.10.024","DOI":"10.1016\/j.cell.2016.10.024"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Vahedi G, Takahashi H, Nakayamada S, Sun H,          Sartorelli V, Kanno Y, O\u2019Shea JJ: STATs shape the active enhancer landscape of T cell          populations. Cell 2012; 151: 981\u2013993. PMID:23178119          https:\/\/doi.org\/10.1016\/j.cell.2012.09.044","DOI":"10.1016\/j.cell.2012.09.044"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Vahedi G, Kanno Y, Furumoto Y, Jiang K, Parker          SC, Erdos MR, Davis SR, Roychoudhuri R, Restifo NP, Gadina M, Tang Z, Ruan Y, Collins FS,          Sartorelli V, O\u2019Shea JJ: Super-enhancers delineate disease-associated regulatory nodes in          T cells. Nature 2015; 520: 558\u2013562. PMID:25686607          https:\/\/doi.org\/10.1038\/nature14154","DOI":"10.1038\/nature14154"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Hirahara K, Onodera A, Villarino AV, Bonelli M,          Scium\u00e8 G, Laurence A, Sun HW, Brooks SR, Vahedi G, Shih HY, Gutierrez-Cruz G, Iwata S,          Suzuki R, Mikami Y, Okamoto Y, Nakayama T, Holland SM, Hunter CA, Kanno Y, O\u2019Shea JJ:          Asymmetric action of STAT transcription factors drives transcriptional outputs and          cytokine specificity. Immunity 2015; 42: 877\u2013889. PMID:25992861          https:\/\/doi.org\/10.1016\/j.immuni.2015.04.014","DOI":"10.1016\/j.immuni.2015.04.014"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. Tsuchiya H, Ota M, Sumitomo S, Ishigaki K, Suzuki          A, Sakata T, Tsuchida Y, Inui H, Hirose J, Kochi Y, Kadono Y, Shirahige K, Tanaka S,          Yamamoto K, Fujio K: Parsing multiomics landscape of activated synovial fibroblasts          highlights drug targets linked to genetic risk of rheumatoid arthritis. Ann Rheum Dis          2021; 80: 440\u2013450. PMID:33139312","DOI":"10.1136\/annrheumdis-2020-218189"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97. Buechler MB, Pradhan RN, Krishnamurty AT, Cox C,          Calviello AK, Wang AW, Yang YA, Tam L, Caothien R, Roose-Girma M, Modrusan Z, Arron JR,          Bourgon R, M\u00fcller S, Turley SJ: Cross-tissue organization of the fibroblast lineage.          Nature 2021; 593: 575\u2013579. PMID:33981032          https:\/\/doi.org\/10.1038\/s41586-021-03549-5","DOI":"10.1038\/s41586-021-03549-5"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Ota M, Nagafuchi Y, Hatano H, Ishigaki K, Terao          C, Takeshima Y, Yanaoka H, Kobayashi S, Okubo M, Shirai H, Sugimori Y, Maeda J, Nakano M,          Yamada S, Yoshida R, Tsuchiya H, Tsuchida Y, Akizuki S, Yoshifuji H, Ohmura K, Mimori T,          Yoshida K, Kurosaka D, Okada M, Setoguchi K, Kaneko H, Ban N, Yabuki N, Matsuki K, Mutoh          H, Oyama S, Okazaki M, Tsunoda H, Iwasaki Y, Sumitomo S, Shoda H, Kochi Y, Okada Y,          Yamamoto K, Okamura T, Fujio K: Dynamic landscape of immune cell-specific gene regulation          in immune-mediated diseases. Cell 2021; 184: 3006\u20133021. PMID:33930287          https:\/\/doi.org\/10.1016\/j.cell.2021.03.056","DOI":"10.1016\/j.cell.2021.03.056"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. Morrison TA, Hudson WH, Chisolm DA, Kanno Y, Shih          HY, Ahmed R, Henao-Mejia J, Hafner M, O\u2019Shea JJ: Evolving views of long noncoding RNAs and          epigenomic control of lymphocyte state and memory. Cold Spring Harb Perspect Biol 2022;          14: a037952. PMID:34001528 https:\/\/doi.org\/10.1101\/cshperspect.a037952","DOI":"10.1101\/cshperspect.a037952"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. Tanaka Y, Luo Y, O\u2019Shea JJ, Nakayamada S: Janus          kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol          2022; 18: 133\u2013145. PMID:34987201          https:\/\/doi.org\/10.1038\/s41584-021-00726-8","DOI":"10.1038\/s41584-021-00726-8"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101. He Y, Wong AY, Chan EW, Lau WC, Man KK, Chui CS,          Worsley AJ, Wong IC: Efficacy and safety of tofacitinib in the treatment of rheumatoid          arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord 2013; 14: 298.          PMID:24139404 https:\/\/doi.org\/10.1186\/1471-2474-14-298","DOI":"10.1186\/1471-2474-14-298"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102. Charles-Schoeman C, Fleischmann R, Davignon J,          Schwartz H, Turner SM, Beysen C, Milad M, Hellerstein MK, Luo Z, Kaplan IV, Riese R,          Zuckerman A, McInnes IB: Potential mechanisms leading to the abnormal lipid profile in          patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.          Arthritis Rheumatol 2015; 67: 616\u2013625. PMID:25470338          https:\/\/doi.org\/10.1002\/art.38974","DOI":"10.1002\/art.38974"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103. Neurath MF: Targeting immune cell circuits and          trafficking in inflammatory bowel disease. Nat Immunol 2019; 20: 970\u2013979. PMID:31235952          https:\/\/doi.org\/10.1038\/s41590-019-0415-0","DOI":"10.1038\/s41590-019-0415-0"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104. Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire          S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu          D, Woodworth D, Mukherjee A, Zhang H, Healey P, Pan\u00e9s J, OCTAVE Induction 1, OCTAVE          Induction 2, OCTAVE Sustain Investigators: Tofacitinib as induction and maintenance          therapy for ulcerative colitis. N Engl J Med 2017; 376: 1723\u20131736. PMID:28467869          https:\/\/doi.org\/10.1056\/NEJMoa1606910","DOI":"10.1056\/NEJMoa1606910"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105. Feagan BG, Danese S, Loftus EV, Vermeire S,          Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempi\u0144ski R, Filip R, Hospodarskyy I,          Seidler U, Seibold F, Beales IL, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset          C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L: Filgotinib as          induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3          double-blind, randomised, placebo-controlled trial. Lancet 2021; 397: 2372\u20132384.          PMID:34090625 https:\/\/doi.org\/10.1016\/S0140-6736(21)00666-8","DOI":"10.1016\/S0140-6736(21)00666-8"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106. Danese S, Vermeire S, Zhou W, Pangan AL,          Siffledeen J, Greenbloom S, H\u00e9buterne X, D\u2019Haens G, Nakase H, Pan\u00e9s J, Higgins PD,          Juillerat P, Lindsay JO, Loftus EV, Sandborn WJ, Reinisch W, Chen MH, Sanchez Gonzalez Y,          Huang B, Xie W, Liu J, Weinreich MA, Panaccione R: Upadacitinib as induction and          maintenance therapy for moderately to severely active ulcerative colitis: results from          three phase 3, multicentre, double-blind, randomised trials. Lancet 2022; 399: 2113\u20132128.          PMID:35644166 https:\/\/doi.org\/10.1016\/S0140-6736(22)00581-5","DOI":"10.1016\/S0140-6736(22)00581-5"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107. Carloni S, Bertocchi A, Mancinelli S, Bellini M,          Erreni M, Borreca A, Braga D, Giugliano S, Mozzarelli AM, Manganaro D, Fernandez Perez D,          Colombo F, Di Sabatino A, Pasini D, Penna G, Matteoli M, Lodato S, Rescigno M:          Identification of a choroid plexus vascular barrier closing during intestinal          inflammation. Science 2021; 374: 439\u2013448. PMID:34672740          https:\/\/doi.org\/10.1126\/science.abc6108","DOI":"10.1126\/science.abc6108"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108. Chavan SS, Pavlov VA, Tracey KJ: Mechanisms and          therapeutic relevance of neuro-immune communication. Immunity 2017; 46: 927\u2013942.          PMID:28636960 https:\/\/doi.org\/10.1016\/j.immuni.2017.06.008","DOI":"10.1016\/j.immuni.2017.06.008"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109. Matsubara Y, Kiyohara H, Teratani T, Mikami Y,          Kanai T: Organ and brain crosstalk: The liver\u2013brain axis in gastrointestinal, liver, and          pancreatic diseases. Neuropharmacology 2022; 205: 108915. PMID:34919906          https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108915","DOI":"10.1016\/j.neuropharm.2021.108915"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110. Muller PA, Schneeberger M, Matheis F, Wang P,          Kerner Z, Ilanges A, Pellegrino K, del M\u00e1rmol J, Castro TB, Furuichi M, Perkins M, Han W,          Rao A, Pickard AJ, Cross JR, Honda K, de Araujo I, Mucida D: Microbiota modulate          sympathetic neurons via a gut\u2013brain circuit. Nature 2020; 583: 441\u2013446. PMID:32641826          https:\/\/doi.org\/10.1038\/s41586-020-2474-7","DOI":"10.1038\/s41586-020-2474-7"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111. Han W, Tellez LA, Perkins MH, Perez IO, Qu T,          Ferreira J, Ferreira TL, Quinn D, Liu ZW, Gao XB, Kaelberer MM, Boh\u00f3rquez DV,          Shammah-Lagnado SJ, de Lartigue G, de Araujo IE: A neural circuit for gut-induced reward.          Cell 2018; 175: 665\u2013678. PMID:30245012          https:\/\/doi.org\/10.1016\/j.cell.2018.08.049","DOI":"10.1016\/j.cell.2018.08.049"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112. Kaelberer MM, Buchanan KL, Klein ME, Barth BB,          Montoya MM, Shen X, Boh\u00f3rquez DV: A gut\u2013brain neural circuit for nutrient sensory          transduction. Science 2018; 361: eaat5236. PMID:30237325          https:\/\/doi.org\/10.1126\/science.aat5236","DOI":"10.1126\/science.aat5236"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113. Clemmensen C, M\u00fcller TD, Woods SC, Berthoud HR,          Seeley RJ, Tsch\u00f6p MH: Gut\u2013brain cross-talk in metabolic control. Cell 2017; 168: 758\u2013774.          PMID:28235194 https:\/\/doi.org\/10.1016\/j.cell.2017.01.025","DOI":"10.1016\/j.cell.2017.01.025"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114. Godinho-Silva C, Cardoso F, Veiga-Fernandes H:          Neuro\u2013immune cell units: a new paradigm in physiology. Annu Rev Immunol 2019; 37: 19\u201346.          PMID:30379595 https:\/\/doi.org\/10.1146\/annurev-immunol-042718-041812","DOI":"10.1146\/annurev-immunol-042718-041812"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115. Brescia P, Rescigno M: The gut vascular barrier:          a new player in the gut\u2013liver\u2013brain axis. Trends Mol Med 2021; 27: 844\u2013855. PMID:34229973          https:\/\/doi.org\/10.1016\/j.molmed.2021.06.007","DOI":"10.1016\/j.molmed.2021.06.007"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116. Dyson JK, Beuers U, Jones DE, Lohse AW, Hudson M:          Primary sclerosing cholangitis. Lancet 2018; 391: 2547\u20132559. PMID:29452711          https:\/\/doi.org\/10.1016\/S0140-6736(18)30300-3","DOI":"10.1016\/S0140-6736(18)30300-3"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117. Mikami Y, Mizuno S, Nakamoto N, Hayashi A, Sujino          T, Sato T, Kamada N, Matsuoka K, Hisamatsu T, Ebinuma H, Hibi T, Yoshimura A, Kanai T:          Macrophages and dendritic cells emerge in the liver during intestinal inflammation and          predispose the liver to inflammation. PLoS One 2014; 9: e84619. PMID:24392145          https:\/\/doi.org\/10.1371\/journal.pone.0084619","DOI":"10.1371\/journal.pone.0084619"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ,          Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon          JI, Hoffman HM, Flavell RA: Inflammasome-mediated dysbiosis regulates progression of NAFLD          and obesity. Nature 2012; 482: 179\u2013185. PMID:22297845          https:\/\/doi.org\/10.1038\/nature10809","DOI":"10.1038\/nature10809"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119. Sorribas M, Jakob MO, Yilmaz B, Li H, Stutz D,          Noser Y, de Gottardi A, Moghadamrad S, Hassan M, Albillos A, Franc\u00e9s R, Juanola O, Spadoni          I, Rescigno M, Wiest R: FXR modulates the gut-vascular barrier by regulating the entry          sites for bacterial translocation in experimental cirrhosis. J Hepatol 2019; 71:          1126\u20131140. PMID:31295531 https:\/\/doi.org\/10.1016\/j.jhep.2019.06.017","DOI":"10.1016\/j.jhep.2019.06.017"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120. Mouries J, Brescia P, Silvestri A, Spadoni I,          Sorribas M, Wiest R, Mileti E, Galbiati M, Invernizzi P, Adorini L, Penna G, Rescigno M:          Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic          steatohepatitis development. J Hepatol 2019; 71: 1216\u20131228. PMID:31419514          https:\/\/doi.org\/10.1016\/j.jhep.2019.08.005","DOI":"10.1016\/j.jhep.2019.08.005"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121. Nakamoto N, Sasaki N, Aoki R, Miyamoto K, Suda W,          Teratani T, Suzuki T, Koda Y, Chu PS, Taniki N, Yamaguchi A, Kanamori M, Kamada N, Hattori          M, Ashida H, Sakamoto M, Atarashi K, Narushima S, Yoshimura A, Honda K, Sato T, Kanai T:          Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune          response in primary sclerosing cholangitis. Nat Microbiol 2019; 4: 492\u2013503. PMID:30643240          https:\/\/doi.org\/10.1038\/s41564-018-0333-1","DOI":"10.1038\/s41564-018-0333-1"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122. Taniki N, Nakamoto N, Chu PS, Ichikawa M,          Teratani T, Kanai T: Th17 cells in the liver: balancing autoimmunity and pathogen defense.          Semin Immunopathol 2022; 44: 509\u2013526. PMID:35211777          https:\/\/doi.org\/10.1007\/s00281-022-00917-9","DOI":"10.1007\/s00281-022-00917-9"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123. Taniki N, Nakamoto N, Chu PS, Mikami Y, Amiya T,          Teratani T, Suzuki T, Tsukimi T, Fukuda S, Yamaguchi A, Shiba S, Miyake R, Katayama T,          Ebinuma H, Kanai T: Intestinal barrier regulates immune responses in the liver via          IL-10-producing macrophages. JCI Insight 2018; 3: e91980. PMID:29925685          https:\/\/doi.org\/10.1172\/jci.insight.91980","DOI":"10.1172\/jci.insight.91980"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124. Mikami Y, Tsunoda J, Kiyohara H, Taniki N,          Teratani T, Kanai T: Vagus nerve-mediated intestinal immune regulation: therapeutic          implications for inflammatory bowel diseases. Int Immunol 2022; 34: 97\u2013106.          PMID:34240133","DOI":"10.1093\/intimm\/dxab039"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125. Jacobson A, Yang D, Vella M, Chiu IM: The          intestinal neuro-immune axis: crosstalk between neurons, immune cells, and microbes.          Mucosal Immunol 2021; 14: 555\u2013565. PMID:33542493          https:\/\/doi.org\/10.1038\/s41385-020-00368-1","DOI":"10.1038\/s41385-020-00368-1"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126. Imai J, Katagiri H: Regulation of systemic          metabolism by the autonomic nervous system consisting of afferent and efferent          innervation. Int Immunol 2022; 34: 67\u201379. PMID:33982088","DOI":"10.1093\/intimm\/dxab023"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127. Honda K, Littman DR: The microbiota in adaptive          immune homeostasis and disease. Nature 2016; 535: 75\u201384. PMID:27383982          https:\/\/doi.org\/10.1038\/nature18848","DOI":"10.1038\/nature18848"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128. Teratani T, Mikami Y, Nakamoto N, Suzuki T,          Harada Y, Okabayashi K, Hagihara Y, Taniki N, Kohno K, Shibata S, Miyamoto K, Ishigame H,          Chu PS, Sujino T, Suda W, Hattori M, Matsui M, Okada T, Okano H, Inoue M, Yada T, Kitagawa          Y, Yoshimura A, Tanida M, Tsuda M, Iwasaki Y, Kanai T: The liver\u2013brain\u2013gut neural arc          maintains the Treg cell niche in the gut. Nature 2020; 585: 591\u2013596. PMID:32526765          https:\/\/doi.org\/10.1038\/s41586-020-2425-3","DOI":"10.1038\/s41586-020-2425-3"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129. Frolkis AD, Vallerand IA, Shaheen AA, Lowerison          MW, Swain MG, Barnabe C, Patten SB, Kaplan GG: Depression increases the risk of          inflammatory bowel disease, which may be mitigated by the use of antidepressants in the          treatment of depression. Gut 2019; 68: 1606\u20131612. PMID:30337374          https:\/\/doi.org\/10.1136\/gutjnl-2018-317182","DOI":"10.1136\/gutjnl-2018-317182"},{"key":"130","doi-asserted-by":"crossref","unstructured":"130. Barberio B, Zamani M, Black CJ, Savarino EV, Ford          AC: Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel          disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021; 6:          359\u2013370. PMID:33721557 https:\/\/doi.org\/10.1016\/S2468-1253(21)00014-5","DOI":"10.1016\/S2468-1253(21)00014-5"},{"key":"131","doi-asserted-by":"crossref","unstructured":"131. Liu B, Wanders A, Wirdefeldt K, Sj\u00f6lander A,          Sachs MC, Eberhardson M, Ye W, Ekbom A, Ol\u00e9n O, Ludvigsson JF: Vagotomy and subsequent          risk of inflammatory bowel disease: a nationwide register-based matched cohort study.          Aliment Pharmacol Ther 2020; 51: 1022\u20131030. PMID:32319125          https:\/\/doi.org\/10.1111\/apt.15715","DOI":"10.1111\/apt.15715"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132. Chu C, Artis D, Chiu IM: Neuro-immune          interactions in the tissues. Immunity 2020; 52: 464\u2013474. PMID:32187517          https:\/\/doi.org\/10.1016\/j.immuni.2020.02.017","DOI":"10.1016\/j.immuni.2020.02.017"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133. Klose CS, Artis D: Neuronal regulation of innate          lymphoid cells. Curr Opin Immunol 2019; 56: 94\u201399. PMID:30530300          https:\/\/doi.org\/10.1016\/j.coi.2018.11.002","DOI":"10.1016\/j.coi.2018.11.002"},{"key":"134","doi-asserted-by":"crossref","unstructured":"134. Kabata H, Artis D: Neuro-immune crosstalk and          allergic inflammation. J Clin Invest 2019; 129: 1475\u20131482. PMID:30829650          https:\/\/doi.org\/10.1172\/JCI124609","DOI":"10.1172\/JCI124609"},{"key":"135","doi-asserted-by":"crossref","unstructured":"135. Huh JR, Veiga-Fernandes H: Neuroimmune circuits          in inter-organ communication. Nat Rev Immunol 2020; 20: 217\u2013228. PMID:31848462          https:\/\/doi.org\/10.1038\/s41577-019-0247-z","DOI":"10.1038\/s41577-019-0247-z"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136. Jarick KJ, Topczewska PM, Jakob MO, Yano H,          Arifuzzaman M, Gao X, Boulekou S, Stokic-Trtica V, Lecl\u00e8re PS, Preu\u00dfer A, Rompe ZA, Stamm          A, Tsou AM, Chu C, Heinrich FR, Guerra GM, Durek P, Ivanov A, Beule D, Helfrich S, Duerr          CU, K\u00fchl AA, Stehle C, Romagnani C, Mashreghi MF, Diefenbach A, Artis D, Klose CS:          Non-redundant functions of group 2 innate lymphoid cells. Nature 2022; 611: 794\u2013800.          PMID:36323785 https:\/\/doi.org\/10.1038\/s41586-022-05395-5","DOI":"10.1038\/s41586-022-05395-5"},{"key":"137","doi-asserted-by":"crossref","unstructured":"137. Klose CS, Mahlak\u00f5iv T, Moeller JB, Rankin LC,          Flamar AL, Kabata H, Monticelli LA, Moriyama S, Putzel GG, Rakhilin N, Shen X, Kostenis E,          K\u00f6nig GM, Senda T, Carpenter D, Farber DL, Artis D: The neuropeptide neuromedin U          stimulates innate lymphoid cells and type 2 inflammation. Nature 2017; 549: 282\u2013286.          PMID:28869965 https:\/\/doi.org\/10.1038\/nature23676","DOI":"10.1038\/nature23676"},{"key":"138","doi-asserted-by":"crossref","unstructured":"138. Wallrapp A, Riesenfeld SJ, Burkett PR, Abdulnour          RE, Nyman J, Dionne D, Hofree M, Cuoco MS, Rodman C, Farouq D, Haas BJ, Tickle TL,          Trombetta JJ, Baral P, Klose CS, Mahlak\u00f5iv T, Artis D, Rozenblatt-Rosen O, Chiu IM, Levy          BD, Kowalczyk MS, Regev A, Kuchroo VK: The neuropeptide NMU amplifies ILC2-driven allergic          lung inflammation. Nature 2017; 549: 351\u2013356. PMID:28902842          https:\/\/doi.org\/10.1038\/nature24029","DOI":"10.1038\/nature24029"},{"key":"139","doi-asserted-by":"crossref","unstructured":"139. Nagashima H, Mahlak\u00f5iv T, Shih HY, Davis FP,          Meylan F, Huang Y, Harrison OJ, Yao C, Mikami Y, Urban JF, Caron KM, Belkaid Y, Kanno Y,          Artis D, O\u2019Shea JJ: Neuropeptide CGRP limits group 2 innate lymphoid cell responses and          constrains type 2 inflammation. Immunity 2019; 51: 682\u2013695. PMID:31353223          https:\/\/doi.org\/10.1016\/j.immuni.2019.06.009","DOI":"10.1016\/j.immuni.2019.06.009"},{"key":"140","doi-asserted-by":"crossref","unstructured":"140. Wallrapp A, Burkett PR, Riesenfeld SJ, Kim SJ,          Christian E, Abdulnour RE, Thakore PI, Schnell A, Lambden C, Herbst RH, Khan P, Tsujikawa          K, Xavier RJ, Chiu IM, Levy BD, Regev A, Kuchroo VK: Calcitonin gene-related peptide          negatively regulates alarmin-driven type 2 innate lymphoid cell responses. immunity 2019;          51: 709\u2013723. PMID:31604686 https:\/\/doi.org\/10.1016\/j.immuni.2019.09.005","DOI":"10.1016\/j.immuni.2019.09.005"},{"key":"141","doi-asserted-by":"crossref","unstructured":"141. Xu H, Ding J, Porter CB, Wallrapp A, Tabaka M, Ma          S, Fu S, Guo X, Riesenfeld SJ, Su C, Dionne D, Nguyen LT, Lefkovith A, Ashenberg O,          Burkett PR, Shi HN, Rozenblatt-Rosen O, Graham DB, Kuchroo VK, Regev A, Xavier RJ:          Transcriptional atlas of intestinal immune cells reveals that neuropeptide \u03b1-CGRP          modulates group 2 innate lymphoid cell responses. Immunity 2019; 51: 696\u2013708.          PMID:31618654 https:\/\/doi.org\/10.1016\/j.immuni.2019.09.004","DOI":"10.1016\/j.immuni.2019.09.004"},{"key":"142","doi-asserted-by":"crossref","unstructured":"142. Kabata H, Moro K, Koyasu S: The group 2 innate          lymphoid cell (ILC2) regulatory network and its underlying mechanisms. Immunol Rev 2018;          286: 37\u201352. PMID:30294963 https:\/\/doi.org\/10.1111\/imr.12706","DOI":"10.1111\/imr.12706"},{"key":"143","doi-asserted-by":"crossref","unstructured":"143. Gabanyi I, Muller PA, Feighery L, Oliveira TY,          Costa-Pinto FA, Mucida D: Neuro-immune interactions drive tissue programming in intestinal          macrophages. Cell 2016; 164: 378\u2013391. PMID:26777404          https:\/\/doi.org\/10.1016\/j.cell.2015.12.023","DOI":"10.1016\/j.cell.2015.12.023"},{"key":"144","doi-asserted-by":"crossref","unstructured":"144. Matheis F, Muller PA, Graves CL, Gabanyi I,          Kerner ZJ, Costa-Borges D, Ahrends T, Rosenstiel P, Mucida D: Adrenergic signaling in          muscularis macrophages limits infection-induced neuronal loss. Cell 2020; 180: 64\u201378.          PMID:31923400 https:\/\/doi.org\/10.1016\/j.cell.2019.12.002","DOI":"10.1016\/j.cell.2019.12.002"},{"key":"145","doi-asserted-by":"crossref","unstructured":"145. Teratani T, Mikami Y, Nakamoto N, Suzuki T,          Harada Y, Okabayashi K, Hagihara Y, Taniki N, Kohno K, Shibata S, Miyamoto K, Ishigame H,          Chu PS, Sujino T, Suda W, Hattori M, Matsui M, Okada T, Okano H, Inoue M, Yada T, Kitagawa          Y, Yoshimura A, Tanida M, Tsuda M, Iwasaki Y, Kanai T: The liver\u2013brain\u2013gut neural arc          maintains the Treg cell niche in the gut. Nature 2020; 585: 591\u2013596. PMID:32526765          https:\/\/doi.org\/10.1038\/s41586-020-2425-3","DOI":"10.1038\/s41586-020-2425-3"},{"key":"146","doi-asserted-by":"crossref","unstructured":"146. Yan Y, Ramanan D, Rozenberg M, McGovern K,          Rastelli D, Vijaykumar B, Yaghi O, Voisin T, Mosaheb M, Chiu I, Itzkovitz S, Rao M, Mathis          D, Benoist C: Interleukin-6 produced by enteric neurons regulates the number and phenotype          of microbe-responsive regulatory T cells in the gut. Immunity 2021; 54: 499\u2013513.          PMID:33691135 https:\/\/doi.org\/10.1016\/j.immuni.2021.02.002","DOI":"10.1016\/j.immuni.2021.02.002"},{"key":"147","doi-asserted-by":"crossref","unstructured":"147. Ghia JE, Blennerhassett P, Kumar-Ondiveeran H,          Verdu EF, Collins SM: The vagus nerve: a tonic inhibitory influence associated with          inflammatory bowel disease in a murine model. Gastroenterology 2006; 131: 1122\u20131130.          PMID:17030182 https:\/\/doi.org\/10.1053\/j.gastro.2006.08.016","DOI":"10.1053\/j.gastro.2006.08.016"},{"key":"148","doi-asserted-by":"crossref","unstructured":"148. Bonaz B, Sinniger V, Hoffmann D, Claren\u00e7on D,          Mathieu N, Dantzer C, Vercueil L, Picq C, Trocm\u00e9 C, Faure P, Cracowski JL, Pellissier S:          Chronic vagus nerve stimulation in Crohn\u2019s disease: a 6-month follow-up pilot study.          Neurogastroenterol Motil 2016; 28: 948\u2013953. PMID:26920654          https:\/\/doi.org\/10.1111\/nmo.12792","DOI":"10.1111\/nmo.12792"}],"container-title":["The Keio Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kjm\/72\/2\/72_2022-0015-IR\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:14:17Z","timestamp":1715318057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kjm\/72\/2\/72_2022-0015-IR\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":148,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2302\/kjm.2022-0015-ir","relation":{},"ISSN":["0022-9717","1880-1293"],"issn-type":[{"value":"0022-9717","type":"print"},{"value":"1880-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"2022-0015-IR"}}